An investigational radiopharmaceutical agent for scintigraphic breast imaging is safe and effective, and it could prove useful for monitoring cancer treatment response, according to a study from Scandinavia.
An investigational radiopharmaceutical agent for scintigraphic breast imaging is safe and effective, and it could prove useful for monitoring cancer treatment response, according to a study from Scandinavia.
The agent, technetium-99m NC100692, is a small peptide that binds to integrin receptors during stages of tumor angiogenesis. This agent could provide valuable physiological information about lesions.
Researchers at the Karolinska Institute of Stockholm and the Norwegian Radiumhospital in Oslo tested the radiopharmaceutical in a nonblinded study of 16 patients with suspicious mammograms and four patients with benign breast lesions. All lesions measured 6 mm or more.
Imaging results were compared with pathology reports, and the research findings were published in the September Journal of Nuclear Medicine.
Twenty lesions were evident on mammography and ultrasound, while two cancers were picked up on pathology alone. Imaging with the new agent detected 19 out of 22 malignant lesions (86%). Missed lesions included one ductal carcinoma in situ and two cases of invasive lobular carcinoma.
No serious adverse events were encountered with the new agent, though mild side effects occurred in five patients, according to the study.
In publishing the results, the researchers noted that scintimammography has been performed with Tc-99m sestamibi to support mammography, but it has shown a sensitivity of just 50% for lesions less than 12 mm. In the new study, lesion size ranged from 5 mm to 40 mm, and Tc-99m NC100692 detected all lesions greater than or equal to 10 mm.
The researchers concluded that the new agent could potentially be used to assess whether chemotherapy treatment is working by assessing angiogenesis. It could play a similar role in other cancers.
For further information from the Diagnostic Imaging archives:
Breast-specific gamma imaging hunts for cancer
Adjunctive breast imaging modalities come up short
Technique adds dimension to nuclear mammography
Scintigraphy/mammography combo could replace biopsy in developing countries
Large Study Affirms Safety of Ultrasound Enhancing Agents for Echocardiography
May 16th 2025Those receiving ultrasound enhancing agents (UEAs) for transthoracic or stress echocardiography had lower odds of all-cause death in comparison to patients who did not have UEAs, according to a nationwide study involving 11.4 million patients.
BrightHeart Garners Third FDA Clearance for AI-Powered Assessments of Fetal Heart Ultrasound
May 14th 2025The latest FDA 510(k) clearance is for B-Right Views, an AI-enabled device, which provides automated detection of required views necessary for second- and third-trimester fetal heart ultrasound exams.